
Today on Drug Discovery & Development
Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design
Recursion's Phase 3 trial of REC-4881 in familial adenomatous polyposis will count removal of adenomas 10 mm or larger as events under an FDA-agreed design.After six years in stealth, Humanitas bets on hybrid AI for drug discovery
Humanitas Global Health launched at AAPS PharmSci 360 with LSU's DeepDrug, which pairs an LLM with a hypergraph for drug design and prescription safety.Drug Discovery and Development See More >

Unlocking PROTAC potential through better delivery
PROTACs (proteolysis-targeting chimeras) are an emerging class of drug molecules designed to eliminate disease-causing proteins rather than simply block them. Each PROTAC has two binding ends joined by a chemical linker: one end attaches to the target protein, while the other recruits an E3 ubiquitin ligase, an enzyme that tags proteins for disposal. By bringing…

2026 PharmSci 360 adds tracks on research credibility and post-animal drug development

FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide

As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%

Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration
Sponsored Content See More >
Genomics/Proteomics See More >

New antibiotics need AI that gets resistance right
ATCC scientists say AI models that predict antibiotic resistance from genomes need authenticated strains, paired MIC data and shared benchmarks.

New cell imaging method reveals hidden enzyme activity

Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification

Spatial biology: Transforming our understanding of cellular environments
Infectious Disease See More >

New antibiotics need AI that gets resistance right
ATCC scientists say AI models that predict antibiotic resistance from genomes need authenticated strains, paired MIC data and shared benchmarks.

After six years in stealth, Humanitas bets on hybrid AI for drug discovery

Moderna, Merck move toward filing for personalized melanoma therapy as COVID sales lift Q3

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice

AbbVie’s Maviret cured 96% of HCV trial participants. The real world is more complicated.
Oncology See More >

Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
Insilico’s AI-designed pan-TEAD inhibitor ISM6331 produced responses in 4 of 22 pretreated mesothelioma patients; a Phase 2a is planned for 2027.

What real-world data shows about current cancer care

Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
























